UP Hospital Sealed After Patient Dies Due To Anaesthesia Overdose

Bhadohi (UP) : An FIR has been registered against a doctor of a private hospital here and other staff members following the death of a young man allegedly due to overdose of anaesthesia for surgery, police said on Monday.

Based on the instructions of District Magistrate Gaurang Rathi, the registration of the hospital has been suspended and its director slapped with a fine of ₹ 2.5 lakh, while authorities have also sealed the medical facility.

Chief Medical Officer (CMO) Santosh Kumar Chak said Vinay Tiwari, resident of Aurai, had gone to the private hospital in Ram Raipur on November 30 last year with the complaint of stomach pain and the director of the hospital, Dr Ganesh Yadav, and his wife, Dr Sushila Yadav, asked him to undergo an operation saying that he was suffering from appendicitis.

Mr Tiwari was admitted to the hospital on the advice of doctors and was sedated before the operation and soon the doctors realized that there had been an overdose of anaesthesia so they decided not to go ahead with the planned surgery.

With his condition worsening, the doctors asked Mr Tiwari’s family to take him, the CMO said, adding that when the family saw him, he had already died. His relatives created a ruckus in the hospital, accusing the doctors of negligence.

The CMO said on the instructions of the DM, a team of three doctors was asked to investigate the cause of death. The report cited an overdose of anaesthesia as the cause of death.

Action is being taken against Dr Ganesh Yadav and other staff members by registering a case under Indian Penal Code section 304-A (death by negligence in treatment), the CMO said.

  • Related Posts

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    New Delhi: AstraZeneca’s India-arm has partnered with National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, to build clinical research capabilities at 25 emerging geographies in a bid to extend…

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into papillary-only non-muscle-invasive bladder cancer (NMIBC). Wednesday’s approval comes nearly three months ahead…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    AstraZeneca, NIPER Raebareli partner to upgrade 25 clinical trail sites

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    Sun Pharma Approves Rs 10,000 Crore Fundraising Through NCDs

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    ‘Bone Bonding’ between Mothers and Children, thanks to Meticulous Bone Grafting

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    Governments have moved for Price Transparency in Hospitals to help patients cope with bills

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction